The assay, GeneSeq: Cardio, is used to identify patients who may require regular cardiac screening, lifestyle changes, or clinical intervention to prevent the progression of myocardial infarction, stroke, sudden cardiac death and secondary complications.
LabCorp chief medical officer Mark Brecher said, "This assay complements our broad testing menu and enhanced reporting for cardiovascular disease."
LabCorp chairman and chief executive officer David King said the new sequencing assay is a significant milestone, as the company embraces new technologies and bioinformatics to further its ability to service patients and physicians.
"We will continue to launch next generation assays to provide the most comprehensive, cost-effective diagnostic tools for multiple disease states," King added.
